• Je něco špatně v tomto záznamu ?

Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis

M. Mahdal, L. Pazourek, V. Apostolopoulos, D. Adámková Krákorová, I. Staniczková Zambo, T. Tomáš

. 2022 ; 29 (5) : 3519-3530. [pub] 20220513

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018410

BACKGROUND: The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. METHODS: The selected group covered patients with bone metastasis who were surgically treated with an intercalary endoprosthesis between 2012 and 2021. The functional outcome was evaluated with the Musculoskeletal Tumor Society (MSTS) scoring system, and complications were evaluated by using the failure classification for prosthetics designed by Henderson. RESULTS: The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure-aseptic loosening (5 cases, 18.5%)-and type III failure-structural failure (2 cases, 7.4%)-occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22-151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). CONCLUSIONS: The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018410
003      
CZ-PrNML
005      
20220804134744.0
007      
ta
008      
220720s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol29050284 $2 doi
035    __
$a (PubMed)35621674
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Mahdal, Michal $u First Department of Orthopedic Surgery, St. Anne's University Hospital, 65691 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic $1 https://orcid.org/0000000221369136
245    10
$a Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis / $c M. Mahdal, L. Pazourek, V. Apostolopoulos, D. Adámková Krákorová, I. Staniczková Zambo, T. Tomáš
520    9_
$a BACKGROUND: The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. METHODS: The selected group covered patients with bone metastasis who were surgically treated with an intercalary endoprosthesis between 2012 and 2021. The functional outcome was evaluated with the Musculoskeletal Tumor Society (MSTS) scoring system, and complications were evaluated by using the failure classification for prosthetics designed by Henderson. RESULTS: The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure-aseptic loosening (5 cases, 18.5%)-and type III failure-structural failure (2 cases, 7.4%)-occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22-151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). CONCLUSIONS: The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.
650    12
$a nádory kostí $x chirurgie $7 D001859
650    _2
$a diafýzy $x chirurgie $7 D018483
650    12
$a nádory femuru $x chirurgie $7 D005266
650    _2
$a femur $x chirurgie $7 D005269
650    _2
$a lidé $7 D006801
650    _2
$a humerus $x chirurgie $7 D006811
650    _2
$a pooperační komplikace $7 D011183
650    _2
$a protézy a implantáty $7 D019736
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pazourek, Lukáš $u First Department of Orthopedic Surgery, St. Anne's University Hospital, 65691 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic $1 https://orcid.org/0000000315351842
700    1_
$a Apostolopoulos, Vasileios $u First Department of Orthopedic Surgery, St. Anne's University Hospital, 65691 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic $1 https://orcid.org/0000000197194769
700    1_
$a Adámková Krákorová, Dagmar $u Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 60200 Brno, Czech Republic $1 https://orcid.org/0000000284022797
700    1_
$a Staniczková Zambo, Iva $u Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic $u First Pathology Department, St. Anne's University Hospital, 65691 Brno, Czech Republic $1 https://orcid.org/0000000211890702
700    1_
$a Tomáš, Tomáš $u First Department of Orthopedic Surgery, St. Anne's University Hospital, 65691 Brno, Czech Republic $u Faculty of Medicine, Masaryk University, 60177 Brno, Czech Republic
773    0_
$w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 29, č. 5 (2022), s. 3519-3530
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35621674 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134738 $b ABA008
999    __
$a ok $b bmc $g 1822144 $s 1169653
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 29 $c 5 $d 3519-3530 $e 20220513 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

    Možnosti archivace